Not independent
Tenure on this board
4.8 yrs
Meeting calendar
PYXS · Annual meeting · Monday, June 15, 2026
Pyxis Oncology Inc
3 nominees · 3 ballot items.
Stockholders will vote to elect three Class II directors, ratify Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal year 2026, and consider any other business properly presented at the Annual Meeting.
Market cap
$191M
1Y TSR
+142.5%
Board grade
C
Record date
Apr 20, 2026
Filing
DEF 14A
Meeting concluded · Jun 15, 2026
Follow how the vote landed and what changed on Pyxis Oncology Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Three Class II Directors
ManagementBoard: FORElect Thomas Civik, Freda Lewis-Hall, M.D., and Michael A. Metzger as Class II directors to serve until the 2029 annual meeting (three-year terms).
- 2
Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for Fiscal Year Ending December 31, 2026
ManagementBoard: FORRatify the Audit Committee’s appointment of Ernst & Young LLP as Pyxis Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 3
Transaction of Other Business
ManagementConsider and vote on any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
4.8 yrs
Independent
Tenure on this board
2.2 yrs
Also a director at
Syndax Pharmaceuticals Inc (SNDX)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | PFIZER INC | 11.1% | 7,032,770 | $9M |
| 2 | Laurion Capital Management LP | 7.9% | 4,997,333 | $7M |
| 3 | GordonMD Global Investments LP | 6.5% | 4,121,870 | $6M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 2,033,510 | $3M |
| 5 | Palo Alto Investors LP | 1.6% | 1,010,510 | $1M |
| 6 | 683 Capital Management, LLC | 1.4% | 896,263 | $1M |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1.4% | 888,680 | $1M |
| 8 | Longaeva Partners L.P. | 0.8% | 503,214 | $735K |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.8% | 485,300 | $709K |
| 10 | BlackRock, Inc. | 0.7% | 468,861 | $685K |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Pyxis Oncology Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Anavex Life Sciences CorpAVXL
Annual meeting·Sep 24, 2026·$303M
Simulations Plus IncSLP
Special meeting·Aug 27, 2026·$370M
Canopy Growth CorpCGC
Annual meeting·Sep 25, 2026·$427M
Ocugen IncOCGN
Special meeting·Sep 21, 2026·$458M
Artiva Biotherapeutics IncARTV
Annual meeting·Sep 8, 2026·$553M
Replimune Group IncREPL
Annual meeting·Sep 15, 2026·$1.3B
Reference
Frequently asked questions
- When is the Pyxis Oncology Inc 2026 annual meeting?
- Pyxis Oncology Inc (PYXS) holds its 2026 annual shareholder meeting on Monday, June 15, 2026.
- What is the record date for the Pyxis Oncology Inc 2026 meeting?
- The record date for the Pyxis Oncology Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Pyxis Oncology Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Pyxis Oncology Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Pyxis Oncology Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Pyxis Oncology Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.